GHRP-2 directly attenuated dexamethasone-induced muscle atrophy gene expression (atrogin-1, MuRF1) in myocytes through GHS-R activation, demonstrating direct muscle-protective effects independent of systemic GH release.
Key findingGHRP-2 directly reduced dexamethasone-induced muscle atrophy gene expression (atrogin-1/MAFbx, MuRF1) in C2C12 myocytes via GHS-R — demonstrating dire
What the researchers found
GHRP-2 directly reduced dexamethasone-induced muscle atrophy gene expression (atrogin-1/MAFbx, MuRF1) in C2C12 myocytes via GHS-R — demonstrating direct GH-independent muscle-protective effects against steroid-induced catabolism at the cellular level.
Why it matters
Relevant for ghrp, muscle-recovery, hormone-optimization.
How the study worked
animal-study study.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1.
Life sciences, 82(9-10), 460-6
Citation
Yamamoto, Daisuke; Ikeshita, Nobuko; Matsubara, Takako; Tasaki, Hiromitsu; Herningtyas, Elizabeth Henny; Toda, Keizo; Iida, Keiji; Takahashi, Yutaka; Kaji, Hidesuke; Chihara, Kazuo; Okimura, Yasuhiko. (2008). GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1.. Life sciences, 82(9-10), 460-6. https://doi.org/10.1016/j.lfs.2007.11.019